Krka believes that its financial results for the first six months of the year “are encouraging and that we will meet our plans for 2024,” after its prescription Pharmaceuticals sales rose by 9% to €823.4m ($897m), helping towards a “strong group EBITDA margin of 28.8%, which is well above the strategic guidance.”
Krka Enjoys 9% Pharma Sales Growth At The Half-Way Stage
Growth In All Six Geographic Segments Aids Krka; EBITDA Margin Above Guidance
Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.
